Related Experiment Video

Updated: Oct 21, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.9K

[Risk of cirrhosis in chronic viral hepatitis patients]

M Latournerie1, O Coatmeur1, P Hillon1

  • 1Hépatogastroentérologie, Hôpital du Bocage, 2 bd Maréchal de Lattre de Tassigny, BP 77 908, 21079 Dijon Cedex.

Virologie (Montrouge, France)
|September 4, 2021
PubMed

Insights

Cirrhosis risk increases with age and alcohol intake in Hepatitis B (HBV) and C (HCV) patients. HIV co-infection and steatosis due to high BMI or metabolic syndrome also worsen liver disease severity.

Area of Science:

  • Hepatology
  • Viral Hepatitis
  • Gastroenterology

Context:

  • Chronic liver diseases caused by Hepatitis B virus (HBV) and Hepatitis C virus (HCV) pose significant global health challenges.
  • Understanding risk factors for disease progression, including cirrhosis and hepatocellular carcinoma (HCC), is crucial for patient management.

Purpose:

  • To identify and summarize key risk factors that exacerbate liver disease severity in patients with chronic HBV and HCV infections.
  • To highlight the emerging role of steatosis and the impact of co-infections and lifestyle factors on disease outcomes.

Summary:

  • Cirrhosis risk is elevated in males and increases exponentially after age 40 for both genders with HBV and HCV.
  • High alcohol consumption (>50g/day) significantly multiplies cirrhosis risk in HBV (6.0x) and HCV (2.4x) patients.
  • HIV co-infection, particularly with CD4 counts <200/mL, worsens HBV and HCV outcomes.
  • Steatosis, linked to high BMI and metabolic syndrome, is a newly identified risk factor for cirrhosis in HBV/HCV and HCC in HCV patients, potentially becoming a major severity predictor.

Impact:

  • Clinicians should consider specific therapeutics targeting these worsening factors alongside antiviral treatment, even with borderline indications.
  • This knowledge aids in personalized risk stratification and proactive management strategies for chronic viral hepatitis.
  • Early identification and management of steatosis and co-infections can mitigate disease progression and improve patient prognosis.

Keywords:
HIV co-infectionalcohol consumptionchronic viral hepatitismetabolic syndrom

More Related Videos

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

636
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.7K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
33
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
181
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
34
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
469
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
35